Home › NCT07743645
Developing Biomarker-Supported Schizophrenia Spectrum Disorder (SSD) Prevention
RecruitingHealthy volunteers welcome
Developing Biomarker-Supported SSD Prevention
Who can join
Ages 9 to 19 · All sexes · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria: * Family history of SSD (defined as first-degree (e.g., a parent or a sibling), second-degree (e.g., an uncle or a grandparent), or other combinations of biological relatives in the family have or likely have a diagnosis of SSD or other closely related severe mental illnesses equivalent to at least 25% of genetic sharing) per medical record review and/or parent/legal guardian report and confirmed by a structured interview * screening positive for two or more risk factors targeted by the intervention * Participants and parent(s)/legal guardian(s) agree to participate * psychiatrically stable and have no major changes in antidepressant, stimulant, or antipsychotic medication in the past 4 weeks. Exclusion Criteria: * Current or past history of psychotic disorders or clinical high risk for psychosis (CHR-p) per study interview * Current or past antipsychotic medication use to specifically treat a psychotic disorder * major medical and neurological conditions * moderate to severe intellectual disabilities or mild intellectual disabilities but expected to have difficulty completing the study assessments; * current drug or alcohol use that impacts functioning and study engagement; * Not able to give assent, permission, or consent. * Not able to undergo MRI.
About the study
The purpose of this study is to compare the effect of a brief family-based psychosocial intervention that addresses modifiable SSD risk factors on persistent and distressing psychotic-like experiences in children and young adults with a family history of SSD and high versus low baseline SSD-like brain patterns
What is being tested
- Psychosocial intervention group (behavioral)
Sponsor: The University of Texas Health Science Center, Houston · Participants: 100 · Started: Sep 1, 2026
Contact the study team
- Yizhou Ma, PhD · Phone: 713-486-2740
- Oluwabunmi Akindona, BA · Phone: 713-486-2740
Official record on ClinicalTrials.gov — NCT07743645
Locations in the U.S.
| Texas | The University of Texas Health Science Center at Houston, Houston |
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.